<DOC>
	<DOCNO>NCT00317980</DOCNO>
	<brief_summary>The purpose study determine whether low-dose pentavalent antimony equally effective compare standard-dose regimen patient cutaneous leishmaniasis . The study do field clinic state Bahia , Brazil .</brief_summary>
	<brief_title>Safety Efficacy Low-Dose Pentavalent Antimony Treatment Cutaneous Leishmaniasis</brief_title>
	<detailed_description>The first-choice drug treatment cutaneous leishmaniasis Brazil pentavalent antimonial meglumine antimoniate . The treatment meglumine antimoniate toxic least relevant adverse event associate drug dose-dependent . Recently , research develop Brazil show evidence lower dos pentavalent antimony equally efficacious compare standard-dose regimen . That evidence obtain patient State Rio de Janeiro infect Leishmania ( Viannia ) braziliensis . The purpose study evaluate safety efficacy low-dose pentavalent antimony regimen patient cutaneous leishmaniasis infect Leishmania ( Viannia ) braziliensis live rural area State Bahia , Brazil , cutaneous leishmaniasis highly endemic . The usefulness study base possibility reduce toxicity observe treatment treatment cost . The main comparison therapeutic response go make two group compose equal number properly randomize patient localized cutaneous leishmaniasis treat follow drug scheme : - Meglumine antimoniate ( calculate dose base concentration pentavalent antimony ) 5 mg/kg/d intravenous 20 day - Meglumine antimoniate ( calculate dose base concentration pentavalent antimony ) 15 mg/kg/d intravenous 20 day The clinical outcome cure failure evaluate third month follow-up .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Presence 1 9 cutaneous lesion clinically compatible leishmaniasis Disease duration 2 20 week Positive leishmanin skin test Parasitological diagnosis confirm culture genusspecific polymerase chain reaction ( PCR ) Leishmania spp History past episode leishmaniasis Mucosal disease Disseminated disease Use drug antileishmanial activity Contraindications use pentavalent antimony : pregnancy renal failure heart failure hepatic failure Other disease : active tuberculosis hanseniasis</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Leishmania braziliensis</keyword>
	<keyword>Pentavalent antimony</keyword>
	<keyword>Meglumine antimoniate</keyword>
</DOC>